CP v2

Tag: Treatment-resistant depression

  • PET brain scans map ketamine’s rapid antidepressant effect, pointing to a potential biomarker for treatment-resistant depression

    PET brain scans map ketamine’s rapid antidepressant effect, pointing to a potential biomarker for treatment-resistant depression

    Researchers in Japan have reported some of the clearest human evidence yet of how ketamine can relieve symptoms of treatment-resistant depression, using PET brain imaging to track changes in key glutamate receptors. The work adds molecular detail to a treatment already known for acting faster than standard antidepressants.

    Major depressive disorder is a leading cause of disability worldwide, and a substantial share of patients do not improve after trying multiple first-line therapies. For those with treatment-resistant depression, ketamine and the related medicine esketamine have drawn attention because some patients feel relief within hours or days rather than weeks.

    What the PET scans measured

    The study, published in Molecular Psychiatry, used a PET tracer called [11C]K-2 designed to visualize AMPA receptors, proteins that help regulate communication between brain cells. Scientists have long suspected that AMPA receptor activity is central to ketamine’s antidepressant effects, but direct confirmation in living people has been limited.

    The researchers combined data from three clinical trials, comparing 34 patients with treatment-resistant depression against 49 healthy participants. Patients received intravenous ketamine or placebo over a two-week period, with PET scans taken before treatment and after the final infusion.

    Receptor shifts tied to symptom relief

    Before treatment, the PET data suggested patients with treatment-resistant depression had region-specific differences in AMPA receptor availability compared with healthy controls. After ketamine, the brain changes were not uniform, instead appearing as shifts in particular areas involved in mood and reward processing.

    Crucially, the degree and location of AMPA receptor changes tracked with how much a patient’s depressive symptoms improved. The authors highlighted especially notable shifts in regions linked in prior research to depression circuitry, arguing the images provide a direct bridge between earlier animal findings and human clinical response.

    Why it could matter clinically

    If replicated, AMPA receptor PET imaging could become a candidate biomarker to help predict who is most likely to benefit from ketamine, and to guide dosing or treatment strategies. That could be valuable because ketamine response can vary, and clinicians are seeking ways to personalize care while balancing benefit, side effects, and monitoring needs.

    The researchers caution that PET imaging is complex and not widely available, and larger studies would be needed before it could influence routine practice. Still, mapping ketamine’s effects at the receptor level may also support development of new rapid-acting antidepressants that target similar pathways with fewer practical barriers.

  • UCLA study suggests accelerated TMS may ease treatment-resistant depression in five days, but follow-up timing matters

    UCLA study suggests accelerated TMS may ease treatment-resistant depression in five days, but follow-up timing matters

    Researchers at UCLA Health say an accelerated form of transcranial magnetic stimulation, or TMS, may deliver comparable symptom relief for some people with treatment-resistant depression in just five days. The approach aims to reduce the practical burden of the standard schedule, which typically requires daily weekday visits over six to eight weeks.

    TMS is a noninvasive brain stimulation therapy that uses magnetic pulses to target regions involved in mood regulation. It is commonly offered when patients do not improve after multiple antidepressant trials, and it has become a widely used option in outpatient psychiatric care.

    A five-by-five TMS schedule

    In the study, clinicians compared a compressed protocol known as 5×5, meaning five sessions per day for five consecutive days, with a conventional six-week course. The analysis included 175 patients, with 40 receiving the accelerated format and 135 receiving standard treatment.

    Both groups saw significant reductions in depression symptoms, and overall outcomes were not meaningfully different between schedules. The findings were published in the Journal of Affective Disorders, and the authors noted the results could expand access for patients who struggle to attend weeks of appointments.

    Why follow-up may change results

    One key observation was that some patients in the accelerated group did not appear to improve immediately after the five-day course ended. When assessed again two to four weeks later, those individuals showed substantial improvement, with depression scores falling by an average of 36%.

    That pattern suggests end-of-week assessments may underestimate the benefit of accelerated TMS for certain patients. The researchers said timing could be important when clinicians and patients decide whether a short course is working.

    What the study did not prove

    The researchers cautioned that the comparison was not a randomized clinical trial, meaning patients were not randomly assigned to the accelerated or standard schedule. They also reported that the traditional course performed better on some longer-term measures, underscoring the need for larger controlled trials.

    Even so, the team argues that a shorter TMS pathway could help more eligible patients start and complete care, especially those facing transportation, work, or caregiving barriers. Further research is expected to refine who benefits most, and whether booster sessions after a short course improve durability.